Outsourcing Services – EU & UK Regulatory & Compliance Support

Flexible, full-spectrum outsourcing solutions for human and veterinary medicinal products. Pharmafile acts as an extension of your regulatory, quality, and pharmacovigilance teams or as a fully outsourced function provider, allowing companies to access expert resources and operational capacity on demand while maintaining full compliance. Our services range from taking on end-to-end regulatory affairs management, pharmacovigilance, and GxP quality oversight, to providing experienced project managers and interim staff for critical initiatives or staff vacancies. We embed our specialists within your organisation’s processes under clear agreements, ensuring that all outsourced activities are defined, agreed, and controlled to meet EU and UK requirements. EU GMP Chapter 7  revised in view of the ICH Q10 guideline on the Pharmaceutical Quality System and applicable since 31 January 2013  provides the authoritative guidance on outsourced GMP-regulated activities for medicinal products for both human and veterinary use. With Pharmafile’s support, you retain control and oversight of compliance and quality, as required by regulators, while benefiting from scalable resourcing and broad expertise. We help you avoid the common pitfalls of outsourcing by implementing strong contracts, robust communication pathways, and governance mechanisms that keep you inspection-ready and in charge at all times.

Who This Service Is For

Our outsourcing services are suitable for:

  • Small & Mid-Sized MAHs Lacking In-House Teams: Growing pharmaceutical or biotechnology companies (including those in the veterinary sector) that hold marketing authorisations but have lean internal teams. If you are an MAH without dedicated departments for regulatory affairs, pharmacovigilance, or quality assurance, we provide an immediate, compliant solution acting as your external RA department, QPPV office, or QA unit. This is ideal for SMEs needing to fulfil obligations (e.g. appointing a QP for batch release or a QPPV for pharmacovigilance) without the overhead of full-time hires, especially during early commercial stages or when expanding into new markets with limited local footprint. Pharmafile PV Services Limited has demonstrable experience providing outsourced EU QPPV services, operating from Ireland.
  • Established Companies Facing Resource Gaps or Peaks: Larger organisations that generally manage in-house but experience temporary resource constraints for instance, a surge of workload (like multiple simultaneous licence applications or safety updates), special projects (such as a company-wide compliance remediation), or staff turnover (e.g. parental leave or vacancy in a critical role). We step in as a bridge to prevent any compliance dip during these periods. Our experts can assume interim responsibility as a contract Qualified Person (QP) or QPPV, run a complex variation project, or clear a backlog of regulatory submissions, clearly delineating our role and integrating with your processes during the contract period.
  • Companies Requiring Specialist Expertise or Geographic Support: Organisations that need niche regulatory knowledge or local representation in Europe or the UK. If you are a non-EU company requiring an EU-based QPPV outsourcing to our specialists is a cost-effective solution— on an as-needed basis. This is also beneficial for companies operating in multiple jurisdictions who want a single partner to coordinate regulatory activities across all EU member states and the UK on their behalf, rather than managing multiple local consultants.
  • Efficient Project Execution: Entities that operate a virtual company model (outsourcing most operational functions) or that require end-to-end project management. If you have a decentralised development programme with external CROs and CMOs, we can provide a dedicated project manager to oversee regulatory submissions and ensure all vendors meet their deliverables on schedule. Or, if you are preparing for a marketing authorisation and need someone to drive the entire regulatory workstream (collating data from different sources, managing experts, writing the dossier), our team can take on that role. We excel in coordinating diverse contributors ensuring, for instance, that contract manufacturers, clinical research partners, and local affiliates all work in concert under a cohesive regulatory plan.

Who might not need this service: Companies with fully staffed and scalable internal departments for all regulatory functions, and those seeking purely cost-driven BPO (Business Process Outsourcing) without a focus on compliance and quality culture. Our service is about strategic partnership and compliance excellence; it may not be suitable for firms only looking for the cheapest labour with minimal oversight.

Regulatory Challenges We Address

Maintaining Compliance & Quality Control with Outsourced Functions: When key functions like regulatory submissions, pharmacovigilance case management, or GMP quality assurance are entrusted to external teams, companies risk losing visibility and control. EU GMP Chapter 7 makes it explicit that the Contract Giver is ultimately responsible to ensure processes are in place to assure the control of outsourced activities, and that these processes should incorporate quality risk management principles. We tackle this by establishing robust procedures and communication channels between your organisation and our experts. This ensures that even though tasks are performed externally, you have full transparency and oversight e.g. regular reports, joint quality reviews, and access to all records so you can demonstrate control to inspectors.

Defining Clear Roles & Avoiding Accountability Gaps: A common pitfall in outsourcing is unclear delineation of responsibilities, leading to “I thought you were doing that” scenarios and regulatory non-compliance. We prevent that by collaboratively defining every role and duty in writing upfront. This clarity not only keeps operations smooth but also satisfies regulators that nothing “falls through the cracks.”

Integrating External and Internal Teams Seamlessly: Another challenge is the practical integration of external personnel into internal workflows and systems. Disparate IT systems, different SOPs, and cultural differences can all pose barriers. We address this by being flexible in our approach: our staff are trained on your company’s procedures and use your systems (or we provide harmonised SOPs if you don’t have them). We often sign on as users of client regulatory tracking systems, quality databases, and collaboration tools, so that all records of outsourced activities (from regulatory filings to adverse event reports) are captured where you need them, in real time. The Contract Giver should provide the Contract Acceptor with all the information and knowledge necessary to carry out the contracted operations correctly in accordance with regulations in force and the Marketing Authorisation for the product concerned. Our project leads act as honorary members of your team, participating in internal meetings and using your communication channels, which eliminates the “black box” feeling of outsourcing.

Handling Peaks, Deadlines, and Multiple Projects: Companies frequently struggle with resource bottlenecks e.g. simultaneous regulatory filings in many countries, responding to an unexpected regulatory authority request under time pressure, or preparing for an inspection while keeping up with day-to-day workload. We provide surge capacity and multi-disciplinary teams to handle these spikes. If you suddenly need to compile five marketing authorisation renewals across the EU while also preparing a new variation, we can assign a coordinated team of regulatory professionals to take on the renewals fully, freeing your staff to focus on the variation. We are accustomed to tight timelines and can scale up support quickly preventing scenarios where deadlines are missed or quality suffers because in-house resources were overstretched.

Ensuring Knowledge Transfer and Business Continuity: When outsourcing on a temporary basis (e.g. covering a maternity leave for a Regulatory Affairs Manager or hiring interim QP services), one risk is loss of organisational knowledge or processes falling behind. We mitigate this by emphasising knowledge capture and transfer. Our consultants document all actions, decisions, correspondence, and when the engagement concludes, we provide handover training and documentation to your returning staff or new hires. For longer-term or fully outsourced functions, we maintain a secure knowledge management repository (e.g. a shared regulatory tracker, a living pharmacovigilance database, or a quality management archive. This focus on information management ensures continuity regulators will find that your product files and compliance records remain coherent and up-to-date, regardless of which of our or your personnel handle the tasks over time.

What Regulators Expect

European and UK regulators emphasise that outsourcing does not dilute any regulatory obligations  the company holding the marketing authorisation remains fully responsible for compliance:

  • Clear Agreements & Defined Responsibilities: There must be a written contract between the Contract Giver and the Contract Acceptor which clearly establishes the duties of each party. All arrangements for the outsourced activities, including any proposed changes in technical or other arrangements, should be in accordance with regulations in force and the Marketing Authorisation for the product concerned, where applicable. The contract should describe clearly who undertakes each step of the outsourced activity.  During inspections or audits, authorities will ask to see these contracts and may review them to ensure responsibilities are unambiguous and compliant.
  • Effective Oversight & Quality Management: The pharmaceutical quality system of the Contract Giver should include the control and review of any outsourced activities. Prior to outsourcing activities, the Contract Giver is responsible for assessing the legality, suitability and the competence of the Contract Acceptor to carry out successfully the outsourced activities. The Contract Giver should be responsible for reviewing and assessing the records and the results related to the outsourced activities.
  • Contract Acceptor Competence & Restrictions: The Contract Acceptor must be able to carry out satisfactorily the work ordered by the Contract Giver, such as having adequate premises, equipment, knowledge, experience, and competent personnel. The Contract Acceptor should not subcontract to a third party any of the work entrusted to it under the contract without the Contract Giver’s prior evaluation and approval of the arrangements. The Contract Acceptor should not make unauthorised changes, outside the terms of the contract, which may adversely affect the quality of the outsourced activities for the Contract Giver.
  • Pharmacovigilance Oversight When Outsourced: For MAHs outsourcing pharmacovigilance activities, EU Good Pharmacovigilance Practice (GVP) modules establish that the MAH must maintain effective oversight of any contracted PV functions. The QPPV remains legally responsible and must demonstrate active supervision. Enterprise documents confirm that outsourced PV arrangements involve detailed delegation of the EU QPPV and Deputy EU QPPV roles, with structured SOPs and PSMF documentation maintained to demonstrate compliance with EU legislation and GVP guidelines. During pharmacovigilance inspections, authorities will assess whether the MAH effectively governs outsourced PV activities through contracts, audit programmes, performance reviews, and documented oversight.

Our Outsourcing Services Delivery Model

Our delivery model for outsourcing is flexible and modular, designed to integrate with your operations and uphold stringent regulatory standards. Key elements include:

Outsourcing Strategy & Operating Model

We begin by understanding your needs and designing an outsourcing solution tailored to fit your organisation’s structure and risk tolerance:

  • Custom Outsourcing Plan: We work with you to define what functions to outsource and to what extent. This might range from full responsibility for a function (e.g. acting as your Regulatory Department or QPPV office) to providing specific support for defined projects or timeframes (e.g. a dedicated team for a new product submission). We help you decide which activities make sense to outsource for example, routine, resource-intensive tasks (like literature screening, regulatory intelligence gathering, CMC variations drafting) are often candidates, whereas activities requiring close internal coordination might remain in-house. For every function we take on, we outline an operating model: who will be doing the work (named qualified personnel), how they will interface with your team (reporting lines, tools, communication frequency), and what success metrics or KPIs will be monitored.
  • Transition & Knowledge Transfer: If we are assuming an existing function (for instance, taking over pharmacovigilance responsibilities for an established product or stepping in as an interim RA manager), we create a transition plan. This involves handover meetings with your current team or previous provider, review of current procedures and status, and a risk assessment of ongoing activities. Once we fully assume the role, we regularly update your management (at agreed intervals) so you have continuous insight into the tasks we handle.
  • Tailored Operating Model: Depending on your preference, we can operate behind the scenes or with a visible presence. As an embedded extension, our staff can use your corporate email domains and participate in internal systems, appearing to regulators and partners as part of your organisation. Alternatively, if acting as a distinct outsourced unit, we will clearly communicate under our own identity but always emphasise that we represent you as the MAH’s agent. In either case, we establish governance routines for example, monthly steering meetings to review performance, regulatory strategy sessions for upcoming milestones, and formal documentation of decisions  to ensure a unified approach.

Regulatory Affairs & Lifecycle Outsourcing

We can assume responsibility for the full spectrum of regulatory affairs tasks, keeping your product’s lifecycle on track:

  • End-to-End Regulatory Management: We manage all aspects of obtaining and maintaining marketing authorisations in any EU member state or the UK. If you lack an internal RA department, we become your de facto RA team assembling dossiers, submitting them via the appropriate procedures (CP, DCP/MRP, or national routes), and handling all health authority interactions. Post-approval, we take care of variations, renewals, PSUR submissions, and any other regulatory obligations to keep your licences compliant. We might serve as your EU-based representative to file an MA on your behalf, ensure formatting and submission through EMA systems, and act as the contact point for questions from the EMA or MHRA.
  • Peak Workload Support & Expert Consultancy: If you have an RA team but face capacity issues or need specialised expertise, we plug the gaps. We can review and QC critical submissions (a second pair of eyes on your centralised procedure filings), or take on the work of authoring CMC sections or responding to complex Lists of Questions using our network of subject matter experts. We also offer to backfill roles — e.g. if your Head of Regulatory goes on leave, our consultant can serve as the interim head, signing off on submissions and representing you in regulatory meetings. All our regulatory outputs are prepared to be audit-ready and aligned with current guidelines.

Pharmacovigilance Outsourcing

Ensuring continuous safety surveillance and quality compliance is critical; we provide robust frameworks for outsourcing these functions:

  • Pharmacovigilance (PV) Outsourcing: We offer full-service PV solutions, including assuming the role of EU QPPV and establishing or hosting your Pharmacovigilance System Master File (PSMF) on your behalf. Our PV physicians and specialists perform case intake and processing, serious adverse event reporting, periodic safety report preparation, signal detection, literature monitoring everything needed to maintain compliance with GVP. Enterprise documents confirm that MAHs can delegate the role of EU QPPV and Deputy EU QPPV to external service providers, with comprehensive PSMF documentation structured per EU GVP Module II to demonstrate compliance with EU legislation and guidelines on good pharmacovigilance practices. Importantly, we integrate this with your operations: for example, if you outsource PV to us, we ensure your QPPV has effective oversight, providing regular safety summaries and immediate escalation pathways for potential safety concerns.

Project Management & Temporary Resourcing

Many companies need short-term expertise or project-based support  we provide professionals and leadership on demand:

  • Interim Staffing Solutions: We can place experienced regulatory professionals in your organisation on a temporary basis. If your Regulatory Affairs Manager goes on sabbatical, our consultant can step in to manage your team and ongoing submissions for the interim. These staff operate under our oversight but work day-to-day within your operations, following your procedures and using your systems. This ensures continuity of operations and compliance. We also handle all the administrative overhead (recruitment, training, salary, etc.), so you can focus on strategic outcomes rather than people management.
  • Project-Based Engagements: For defined projects (e.g. a large-scale MA submission, a compliance remediation project after an audit, integration of a newly acquired product’s regulatory framework, or preparing for an agency inspection), we assemble a dedicated project team. We develop a project plan with clear milestones and deliverables, and we bring multi-disciplinary experts as needed perhaps a regulatory CMC expert, a labelling specialist, etc.  to ensure every aspect is covered. Our project managers use proven methodologies to keep things on track and report progress to your leadership regularly. Once the project is completed, we conduct a handover to your team, including all documentation generated and any lessons learned.
  • Scalable Support for Growth: As your company grows or enters new markets, your operational needs might expand faster than you can hire and train staff. Our outsourcing model is inherently scalable for example, if you suddenly have a spike in ICSRs (individual case safety reports) due to a product launch, our PV team can quickly ramp up resources to handle the increased volume, then scale down as things stabilise. You avoid the “feast or famine” problem of fixed headcount, while meeting regulatory requirements even during peak periods.

Governance, Oversight & Inspection Readiness

We place strong emphasis on governance and oversight to ensure outsourcing arrangements withstand regulatory scrutiny:

  • Defined Governance Structure: At the outset of an outsourcing relationship, we set up a governance framework. This typically includes identifying counterpart leads on both sides, escalation pathways (e.g. what happens if a quality issue arises), and routine meeting schedules (monthly operational reviews, quarterly governance meetings, annual strategic reviews). We encourage our clients to treat us as they would an internal department when it comes to audits and reviews. We support regular performance metrics tracking: how many submissions made, compliance rates, batch release right-first-time percentage, so you can monitor our performance quantitatively. The Contract Giver should monitor and review the performance of the Contract Acceptor and the identification and implementation of any needed improvement.
  • Auditable Processes & Transparency: We maintain all records related to outsourced work in an auditable manner and make them available to you. The contract should permit the Contract Giver to audit outsourced activities, performed by the Contract Acceptor or mutually agreed subcontractors. We often use shared document repositories or give you direct access to our tracking systems. If we act as your QPPV, we keep the PSMF updated and available for your review at all times. This level of transparency not only keeps you in control but also means that, in an inspection, you can provide evidence of how you oversee our work.
  • Inspection Support and Representation: When you undergo an inspection or audit, we stand by you. If our outsourced activities are in scope for example, an MHRA GVP inspector might want to interview the QPPV (which could be our staff member) we will participate actively, presenting the relevant procedures and records. We ensure you have confident answers, backed by documented evidence. Our aim is that regulators find the outsourcing arrangement as robust as any internal department.

Jurisdictions Covered

  • European Union & EEA: We ensure all outsourced activities comply with EU directives and guidelines relevant to medicinal products. This encompasses Good Pharmacovigilance Practice (GVP) modules for safety management, and Good Distribution Practice (GDP) for any wholesaling activities. EU GMP Chapter 7 provides guidance under the legal basis of Article 47 of Directive 2001/83/EC (human) and Article 51 of Directive 2001/82/EC (veterinary). Our operations and contracts are designed to hold up under inspections by EU authorities. Because we are based in the EEA (Ireland), we meet the establishment requirements for roles like QPPV or PSMF location by default. We have supported clients across EU/EEA countries and are familiar with national nuances.
  • United Kingdom: Post-Brexit, the UK has its own regulatory regime, but the principles of outsourcing remain consistent. We provide support compliant with UK-specific QPPV services (the MHRA expects a UK contact for pharmacovigilance). Because we have a presence in both the EU and UK, we seamlessly manage outsourcing solutions that span both, ensuring that, for example, an EU QP and UK QP are both in place if needed, and that both sets of regulatory authorities are satisfied.
  • Global Considerations: While our centre of operations is EU/UK, we understand that outsourcing often has a global dimension. We can coordinate with local regulatory consultants in other regions. For globally outsourced pharmacovigilance, we ensure that data flows cover non-EU safety reporting in synergy with EU reporting, so there are no silos. In all cases, we adhere to the highest standard among the applicable regulations, so that compliance is never compromised when operating across multiple regulatory jurisdictions.

Typical Timelines

Outsourcing arrangements can often be set up quickly, but exact timelines depend on the scope of activities, complexity, and any required regulatory notifications or approvals. Below is a general guide for key phases in establishing and running outsourced services (actual timelines may vary based on client readiness and regulatory processing times):

Phase/Activity Estimated Timeline Notes
Initial Assessment & Planning (scoping & contract ~2–4 weeks Includes evaluating needs, defining scope, drafting the technical agreement/contract. Faster if scope is narrow or urgent (we have template agreements ready); longer for broad or multi-party arrangements requiring detailed negotiation.
Transition & Onboarding (for ~4–8 weeks (overlap period) We recommend 1–2 months of overlap where we ramp up and assume responsibilities. For a single-function outsourcing (e.g. QPPV service), this can be done in a few weeks. For multi-function outsourcing (taking over RA, PV, and QA together), expect ~2 months to carefully map processes, transfer knowledge, and get regulatory approvals (like notifying new QPPV to authorities).
Authority Notifications (e.g. QPPV change, site change) Variable (typically days to weeks) EU: QPPV changes are notified via XEVMPD and reflected in PSMF documentation. UK: MHRA requires notification of new QPPV, which can be done through the MHRA portal. Manufacturing site changes or adding new sites via variation can take longer to approve. We align these with the outsourcing start date. (Confirm against current applicable regulatory timescales before publication.)
Full Operation Commencement (go-live as service provider) Immediately after contract & regulatory clearances Once agreements are signed and any required regulatory arrangements are in place, we begin delivering services as per scope. In urgent cases, we can start critical activities under a technical agreement even while formalities are being finalised, ensuring no gap in compliance.
Ongoing Service Review Cycle Monthly (operations) & Quarterly (governance) We typically set monthly operational meetings for status updates and a more formal quarterly review with stakeholders to evaluate performance, KPIs, and any needed adjustments. These ensure continuous alignment and allow fine-tuning of the arrangement.
Scalability Adjustments 2–4 weeks per change Because of our flexible model, expanding scope can often be done within a month or less, depending on hiring/training needs. Similarly, handing back functions (if you decide to insource later) can be done with a 30-day notice in many cases, with a structured handover. We ensure a smooth ramp-down with knowledge transfer if transitioning back in-house.
Contract Renewal or Extension 4–6 weeks before contract end We proactively discuss continuation well before the current term ends, to ensure no disruption of service or to implement a planned exit/handover if needed.

These timelines assume cooperation by all parties and timely availability of required information (e.g. existing procedures, data access) and resources. In practice, we can accommodate faster mobilisations in urgent scenarios  for example, providing an interim QP within 1–2 weeks  through our pool of ready experts. Conversely, for highly complex integrations, timelines might extend slightly to ensure thorough preparation. We always tailor to the client’s situation, balancing speed with diligence. Verify against current internal performance data before publication.

Common Mistakes We Help You Avoid

Our experience has shown several recurring issues in outsourced regulatory and compliance operations. By partnering with us, you sidestep these pitfalls:

  • Lack of Clarity in Roles and Contracts: One major mistake is starting an outsourcing engagement without a sufficiently detailed agreement. This can lead to confusion (for example, who is responsible for updating the SmPC after a variation the in-house team or the service provider?). The contract should describe clearly who undertakes each step of the outsourced activity, e.g. knowledge management, technology transfer, supply chain, subcontracting, quality and purchasing of materials, testing and releasing materials, undertaking production and quality controls. We ensure every duty is clearly defined and documented, delineating communication pathways, decision-making authority, and escalation procedures. This clarity prevents misunderstandings and ensures both parties know exactly what to expect.
  • Insufficient Oversight of the Service Provider: Another common error is adopting a “hands-off” approach after outsourcing, which can lead to compliance drift. Regulators have cited companies for failing to monitor their contractors such as not auditing them or not reviewing the work they do. EU GMP explicitly states that the Contract Giver should monitor and review the performance of the Contract Acceptor and the identification and implementation of any needed improvement. Our approach actively involves you through provided metrics, review cycles, and audit support, so you maintain oversight. We encourage our clients to audit us just as they would an internal department, and we facilitate those audits by being prepared and transparent.
  • Overlooking Regulatory Notifications: Skipping to inform or seek approval from regulators when needed can be costly. If you change your QPPV or add a new manufacturing site through outsourcing, those are subject to regulatory notification or variation. We’ve observed companies forget to notify authorities of a new QPPV after outsourcing PV, leading to non-compliance. We handle all required submissions and even inform regulators proactively when appropriate.
  • Losing Internal Know-How and Control: Sometimes companies outsource and then lose track of the work, leaving them vulnerable if the provider relationship ends. All records related to the outsourced activities must be kept by, or be available to, the Contract Giver. We combat this by implementing robust knowledge management and return of information. All documents we create (regulatory submissions, reports, correspondence logs) are handed over or accessible to you in real time. If our contract ends, you have everything needed to continue seamlessly we even offer a tail-end period to train new internal hires or another provider.
  • Failing to Assess Competence Before Engagement: Prior to outsourcing activities, the Contract Giver is responsible for assessing the legality, suitability and the competence of the Contract Acceptor to carry out successfully the outsourced activities. Some companies bypass this step for speed or convenience, only to discover later that the provider lacks the required expertise, authorisations, or systems. We facilitate this assessment in reverse proactively demonstrating our qualifications, providing evidence of our regulatory experience, and welcoming pre-engagement audits.
  • Choosing Cost over Compliance: It can be tempting to select the cheapest vendor for an outsourced task, but regulators have penalised companies when those vendors underperformed. We emphasise that outsourcing should be about augmenting capability and ensuring compliance, not just cutting cost. Our approach and pricing reflect the true effort needed to maintain compliance. As a result, our clients avoid the scenario of a forced vendor switch (or even product suspension) because an outsourced function failed an inspection.

Frequently Asked Regulatory Questions

Companies outsource for several reasons: to access specialised expertise, to manage workload peaks, to cover resource gaps or staff turnover, and to improve efficiency and cost-effectiveness. A small company might not have an in-house pharmacovigilance team, so they outsource to ensure a qualified QPPV and PV system are in place. Larger companies might use outsourcing to quickly scale up during a new product launch or to handle a one-time project without permanently increasing headcount. Outsourcing can also offer a fresh perspective and best practices from a specialised provider.

Virtually any GMP-regulated activity can be outsourced as long as it is appropriately controlled. This includes regulatory affairs tasks (dossier preparation, licence maintenance), pharmacovigilance (case processing, signal management, QPPV service), GMP operations (manufacturing, packaging, lab testing under contract), Good Distribution Practice (outsourcing warehousing and logistics), and clinical trial management. Even strategic roles like the Qualified Person (for batch release) or the QPPV can be contracted. The law allows outsourcing the work, but not the responsibility.

No  you retain ultimate control and responsibility. The Contract Giver is ultimately responsible to ensure processes are in place to assure the control of outsourced activities. When we provide outsourcing services, we put in place governance measures to keep you in control: you have full visibility into tasks through regular reports and access to data, you approve key decisions, and you hold the contractual right to audit and intervene. If we serve as your QPPV, you as the MAH will still be reviewing safety data and approving risk management measures; we facilitate and execute the process. The idea is that you gain expert execution while ensuring you have the final say.

We handle quality and confidentiality through strict contracts, SOPs, and secure systems. Before starting, we sign detailed confidentiality agreements to protect your data. For quality, we operate under a robust pharmaceutical quality system. We sign a Quality or Technical Agreement that defines how we manage records, deviations, CAPAs, and reviews and that you have the right to audit us. The contract should permit the Contract Giver to audit outsourced activities performed by the Contract Acceptor or mutually agreed subcontractors. We use validated IT systems for document management and safety data; access is permission-controlled and compliant with GDPR for any personal data.

Effective communication is key to successful outsourcing. We tailor communication channels to your preferences: some clients integrate our team in daily internal meetings and instant messaging platforms, others prefer formal weekly email updates. Typically, we establish a communication plan during onboarding  specifying points of contact on both sides, frequency of updates, and escalation paths for urgent issues. The contract should specify responsibilities and communication processes relating to the outsourced activities, with technical aspects drawn up by competent persons suitably knowledgeable in related outsourced activities and Good Manufacturing Practice.

We agree on Key Performance Indicators (KPIs) and governance checkpoints at the contract’s outset. KPIs could include metrics like on-time submission rates, pharmacovigilance compliance rates, number of corrections from authorities (aiming to minimise deficiencies), audit findings, etc. We report these to you regularly. Additionally, we propose quarterly or bi-annual governance meetings to review performance and any issues. The Contract Giver should monitor and review the performance of the Contract Acceptor and the identification and implementation of any needed improvement. If any metric is below target, we initiate a CAPA. Our contract also includes provisions for periodic quality audits.

You can absolutely choose a hybrid approach. Many clients opt to keep certain activities in-house and outsource others. For example, you might retain strategic regulatory activities (like overall clinical development planning) but outsource the time-consuming dossier compilation and publishing tasks. What is important is defining interfaces clearly (e.g. if you handle case intake and we handle assessment, we establish an SOP for handing over cases within an agreed timeframe). Regulators are satisfied with such split responsibility as long as it is clearly documented and there is no ambiguity on who does what. We help ensure that whether it is a full or partial outsource, all parties know their roles and the overall process remains compliant.

We pride ourselves on agility. Depending on the function and scale, we can often provide support within days to a couple of weeks. For a pharmacovigilance emergency (say your QPPV suddenly departs), we can assign one of our QPPVs as an interim within a few days and handle the necessary regulatory notifications while they cover the role. For large projects like a marketing authorisation in-licensing or a series of variations, we can assemble a team rapidly. Our model is built to respond to the reality that in pharma, deadlines are often immovable.

Because regulatory science is our core business, we invest heavily in continuous training and knowledge management. Our consultants participate in professional forums, undergo regular internal training on new guidelines (e.g. updates to EMA guidance, or changes in national requirements), and share insights in weekly knowledge-sharing meetings. We also maintain an internal database of regulatory intelligence (which we use to proactively update client processes when guidelines change). When you outsource to us, you are tapping into a pool of experts who are always up-to-date. As soon as a new GVP Module revision our relevant team will adapt your processes accordingly and inform you of the changes.

It often does, but more importantly it should improve compliance and efficiency. By outsourcing, you convert fixed costs (like salaries, training, infrastructure) into flexible costs that scale with your needs  you pay for the service level you require. You avoid expenses of hiring full-time staff for roles you might not need 12 months a year, and you gain access to a team with broad experience (which can prevent costly mistakes or delays). That said, our focus is not to be the “cheapest” provider, but to provide the best value meaning you get expert quality and peace of mind that regulators will be satisfied. Many clients find that the cost of non-compliance (in fines, recalls, or lost market opportunities) far exceeds what they pay for professional outsourced support.

Related Services & Resources

Outsourcing often blends multiple functional areas. We ensure our services integrate with and complement our other offerings:

  • Regulatory Affairs Management: If you entrust us with regulatory affairs through an outsourcing model, you effectively leverage our full Regulatory Affairs Management capability. We handle strategic planning, dossier assembly, authority communication everything described on our RA Management page but in a long-term, ongoing capacity rather than project-by-project. (See our Regulatory Affairs Management page for specifics on submission strategy, dossier preparation, and lifecycle maintenance.)
  • Pharmacovigilance Services: Our outsourced PV solutions map directly to our Pharmacovigilance Services offering. By outsourcing PV to us, you gain a turnkey solution that includes case management, signal detection, risk management, and regulatory reporting, all under the watch of our QPPVs and in compliance with EU/UK GVP. (Details on our safety monitoring processes are on the Pharmacovigilance Services page.)
  • Quality Services: When you use our quality or GMP compliance outsourcing (e.g. engaging our QP or QA team), you get the benefits of our Quality Services expertise on an ongoing basis. We conduct audits, manage your quality system, and ensure manufacturing or distribution partners are compliant. (Our Quality Services page outlines how we handle GMP, GDP, and GVP compliance tasks.)
  • Medical Writing & eCTD Publishing: If your outsourcing includes regulatory documentation or submissions, our medical writing and publishing specialists will be part of the team. This ensures that important documents (like CTD modules, response letters, or briefing documents) are crafted to high standards. (Refer to Medical Writing & eCTD Publishing for our capabilities in creating and managing submission documents.)
  • Interim Staffing via Our Network: Through our Outsourcing service, you tap into a broad network of professionals. If you initially outsource a single function and later find you need additional support in another area, we can quickly bring in those resources. We commonly provide integrated teams  e.g. an RA project manager working alongside a PV officer and a QA consultant  to cover multiple functions. This interplay is managed internally by Pharmafile, reducing the management burden on you. (Our Licensing Facilitation and Braille Compliance services are examples where we might act as an outsourced team handling specialised regulatory processes.)
  • Knowledge Base & Insights: We believe in empowering our clients, even as we handle tasks for them. Through our Knowledge Centre, we share insights on best practices for managing outsourced activities (for example, how to set up a vendor oversight programme, or tips for passing an inspection when you use third-party service providers). These resources can be useful if you are considering what to outsource or how to manage existing outsourcing relationships.

By combining these resources and services, Pharmafile ensures that outsourcing any part of your regulatory or compliance operations does not mean fragmenting them. We act as a unifying force, coordinating with other stakeholders (internal or external) and keeping the bigger picture in view: that your obligations to regulators and patients are met in full, irrespective of who is doing the work behind the scenes.